Document Detail

Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension.
MedLine Citation:
PMID:  16989601     Owner:  NLM     Status:  MEDLINE    
In recent years, the renin-angiotensin-aldosterone system has been shown to be crucial not only in blood pressure haemostasis but also in the evolution of atherosclerosis, which ultimately determines morbidity and mortality. The angiotensin-converting enzyme inhibitors and, recently, the angiotensin receptor blockers (with their low adverse-effect profile) have added a new dimension to the drug treatment of hypertension. Just a decade after the introduction of angiotensin receptor blockers, physicians treating hypertension are now offered another exciting approach to achieving blockade of the renin-angiotensin-aldosterone system through the inhibition of renin. This review outlines the background evidence for aliskiren, the first orally active renin inhibitor.
Eoin O'Brien
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  15     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-22     Completed Date:  2006-11-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1269-77     Citation Subset:  IM    
The Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / pharmacology,  therapeutic use
Drugs, Investigational / pharmacology,  therapeutic use*
Fumarates / pharmacology,  therapeutic use*
Hypertension / drug therapy*,  metabolism*
Renin / antagonists & inhibitors*,  chemistry,  metabolism
Reg. No./Substance:
0/Amides; 0/Antihypertensive Agents; 0/Drugs, Investigational; 0/Fumarates; 0/aliskiren; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Therapeutic potential of S179D prolactin--from prostate cancer to angioproliferative disorders: the ...
Next Document:  Etanercept for refractory asthma therapy.